Paratek Antibiotic Meets Non-Inferiority Bar In First Phase III
Executive Summary
Paratek's omadacycline was non-inferior to Zyvox (linezolid) in a Phase III clinical trial testing the antibiotics in serious skin infections, but the company's drug will have a broader market that includes pneumonia and urinary tract infections – possibly with reduced competition – if future studies are positive.
You may also be interested in...
Paratek Sees Broad Potential For Omadacycline After Second Phase III Win
Paratek Pharmaceuticals will seek US FDA approval for omadacycline in early 2018 based on a second successful Phase III study for its antibiotic. The company believes the drug has broad potential against multiple pathogens and across multiple patient populations.
ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek
Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.